These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 25145343)

  • 1. NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report.
    Ostronoff F; Othus M; Gerbing RB; Loken MR; Raimondi SC; Hirsch BA; Lange BJ; Petersdorf S; Radich J; Appelbaum FR; Gamis AS; Alonzo TA; Meshinchi S
    Blood; 2014 Oct; 124(15):2400-7. PubMed ID: 25145343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NUP98::NSD1 and FLT3/ITD co-expression is an independent predictor of poor prognosis in pediatric AML patients.
    Wang JW; Yu-Li ; Yang XG; Xu LH
    BMC Pediatr; 2024 Aug; 24(1):547. PubMed ID: 39182032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent co-operation between the NUP98-NSD1 fusion and the FLT3-ITD mutation in acute myeloid leukemia induction.
    Thanasopoulou A; Tzankov A; Schwaller J
    Haematologica; 2014 Sep; 99(9):1465-71. PubMed ID: 24951466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dasatinib and navitoclax act synergistically to target NUP98-NSD1
    Kivioja JL; Thanasopoulou A; Kumar A; Kontro M; Yadav B; Majumder MM; Javarappa KK; Eldfors S; Schwaller J; Porkka K; Heckman CA
    Leukemia; 2019 Jun; 33(6):1360-1372. PubMed ID: 30568173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study.
    Shimada A; Iijima-Yamashita Y; Tawa A; Tomizawa D; Yamada M; Norio S; Watanabe T; Taga T; Iwamoto S; Terui K; Moritake H; Kinoshita A; Takahashi H; Nakayama H; Koh K; Goto H; Kosaka Y; Saito AM; Kiyokawa N; Horibe K; Hara Y; Oki K; Hayashi Y; Tanaka S; Adachi S
    Int J Hematol; 2018 May; 107(5):586-595. PubMed ID: 29330746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical implications of NUP98::NSD1 fusion at diagnosis in adult FLT3-ITD positive AML.
    Miyajima T; Onozawa M; Yoshida S; Miyashita N; Kimura H; Takahashi S; Yokoyama S; Matsukawa T; Goto H; Sugita J; Fujisawa S; Hidaka D; Ogasawara R; Mori A; Matsuoka S; Shigematsu A; Wakasa K; Kasahara I; Saga T; Hashiguchi J; Takeda Y; Ibata M; Yutaka T; Fujimoto K; Kondo T; Teshima T
    Eur J Haematol; 2023 Oct; 111(4):620-627. PubMed ID: 37465857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of acute myeloid leukemia co-expressing NUP98/NSD1 and FLT3/ITD with preemptive donor lymphocyte infusions.
    Mitani Y; Hiwatari M; Seki M; Hangai M; Takita J
    Int J Hematol; 2019 Oct; 110(4):512-516. PubMed ID: 31134509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High PRDM16 expression identifies a prognostic subgroup of pediatric acute myeloid leukaemia correlated to FLT3-ITD, KMT2A-PTD, and NUP98-NSD1: the results of the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 trial.
    Shiba N; Ohki K; Kobayashi T; Hara Y; Yamato G; Tanoshima R; Ichikawa H; Tomizawa D; Park MJ; Shimada A; Sotomatsu M; Arakawa H; Horibe K; Adachi S; Taga T; Tawa A; Hayashi Y
    Br J Haematol; 2016 Feb; 172(4):581-91. PubMed ID: 26684393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of three pediatric AML co-expressing NUP98-NSD1, FLT3-ITD, and WT1.
    Liu L; Nie Q; Xiao Z; Chen X; Yang C; Mao X; Li N; Zhou Y; Guo Q; Tian X
    BMC Pediatr; 2024 Jul; 24(1):483. PubMed ID: 39068406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concealed dagger in FLT3/ITD+ AML.
    Ofran Y
    Blood; 2014 Oct; 124(15):2317-9. PubMed ID: 25301331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
    Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern.
    Hollink IH; van den Heuvel-Eibrink MM; Arentsen-Peters ST; Pratcorona M; Abbas S; Kuipers JE; van Galen JF; Beverloo HB; Sonneveld E; Kaspers GJ; Trka J; Baruchel A; Zimmermann M; Creutzig U; Reinhardt D; Pieters R; Valk PJ; Zwaan CM
    Blood; 2011 Sep; 118(13):3645-56. PubMed ID: 21813447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NUP98-NSD1 fusion in association with FLT3-ITD mutation identifies a prognostically relevant subgroup of pediatric acute myeloid leukemia patients suitable for monitoring by real time quantitative PCR.
    Akiki S; Dyer SA; Grimwade D; Ivey A; Abou-Zeid N; Borrow J; Jeffries S; Caddick J; Newell H; Begum S; Tawana K; Mason J; Velangi M; Griffiths M
    Genes Chromosomes Cancer; 2013 Nov; 52(11):1053-64. PubMed ID: 23999921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of Childhood Acute Myeloid Leukemia With FLT3-ITD Mutation: The Experience of Children's Cancer Hospital Egypt, 2007-17.
    Semary SF; Hammad M; Soliman S; Yassen D; Gamal M; Albeltagy D; Hamdy N; Mahmoud S
    Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):e529-e541. PubMed ID: 32473792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of cooccurring mutations in FLT3-ITD pediatric acute myeloid leukemia.
    Tarlock K; Gerbing RB; Ries RE; Smith JL; Leonti A; Huang BJ; Kirkey D; Robinson L; Peplinski JH; Lange B; Cooper TM; Gamis AS; Kolb EA; Aplenc R; Pollard JA; Alonzo TA; Meshinchi S
    Blood Adv; 2024 May; 8(9):2094-2103. PubMed ID: 38295280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Molecular Characteristics and Clinical Features of Adults with
    Lun Y; Huang JC; Long D; Wang FF; Dai Y; Yang Y; Zhao TT; Li Q; Wu Y
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2018 Jul; 49(4):575-581. PubMed ID: 30378313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutated
    Niktoreh N; Walter C; Zimmermann M; von Neuhoff C; von Neuhoff N; Rasche M; Waack K; Creutzig U; Hanenberg H; Reinhardt D
    J Oncol; 2019; 2019():1609128. PubMed ID: 31467532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis.
    Struski S; Lagarde S; Bories P; Puiseux C; Prade N; Cuccuini W; Pages MP; Bidet A; Gervais C; Lafage-Pochitaloff M; Roche-Lestienne C; Barin C; Penther D; Nadal N; Radford-Weiss I; Collonge-Rame MA; Gaillard B; Mugneret F; Lefebvre C; Bart-Delabesse E; Petit A; Leverger G; Broccardo C; Luquet I; Pasquet M; Delabesse E
    Leukemia; 2017 Mar; 31(3):565-572. PubMed ID: 27694926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Genetic characteristics and clinical outcomes of pediatric acute myeloid leukemia with NUP98-NSD1 fusion gene].
    Wang T; Ni JB; Wang XY; Dai Y; Ma XL; Su YC; Gao YY; Chen X; Yuan LL; Liu HX
    Zhonghua Yi Xue Za Zhi; 2019 Sep; 99(36):2820-2825. PubMed ID: 31550809
    [No Abstract]   [Full Text] [Related]  

  • 20. Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: a report from the Children's Oncology Group.
    Tarlock K; Alonzo TA; Moraleda PP; Gerbing RB; Raimondi SC; Hirsch BA; Ravindranath Y; Lange B; Woods WG; Gamis AS; Meshinchi S
    Br J Haematol; 2014 Jul; 166(2):254-259. PubMed ID: 24661089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.